Methylsulfonylmethane and Sesame Seed Oil Improve Dyslipidemia and Modulate Polyunsaturated Fatty Acid Metabolism in Two Mouse Models of Diabetes

• Published in: Journal of medicinal food Vol. 25; no. 6; p. 607
• Main Authors: Fili, Cameron V, Lin, Ling, Chapman, Jonathan, Hamilton, David, Yates, Charles R
• Format: Journal Article
• Language: English
• Published: United States 01.06.2022
• Subjects: Animals; Blood Glucose - metabolism; Cholesterol; Chromatography, Liquid; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 - drug therapy; Dimethyl Sulfoxide; Dyslipidemias - drug therapy; Fatty Acids, Unsaturated - therapeutic use; Humans; Mice; Mice, Inbred C57BL; Sesame Oil - therapeutic use; Sesamum - metabolism; Streptozocin; Sulfones; Tandem Mass Spectrometry; Triglycerides; sesame seed oil; cholesterol; hyperlipidemia; methylsulfonylmethane; diabetes
• ISSN: 1557-7600
• DOI: 10.1089/jmf.2021.0196

The objective of this study was to identify alterations in lipids and polyunsaturated fatty acid (PUFA) metabolism in both the streptozotocin (STZ)-induced type 1 diabetic (T1D) mouse and the mutant type 2 diabetic (T2D) mouse to establish a biological signature for the evaluation of natural products with purported lipid-altering activity. Eight-week-old male C57BL/6J mice were randomized to nondiabetic group or STZ-induced diabetic groups (  = 10/group). STZ-induced diabetic mice and 6-week-old male mice (  = 10/group) were randomized to the following groups: (1) diabetic control, no treatment, (2) methylsulfonylmethane (MSM) treatment, (3) sesame seed oil (SSO) treatment, and (4) MSM+SSO combination treatment. Clinical parameters measured included weights, blood glucose, serum lipid panels, and liquid chromatography-tandem mass spectrometry (LC-MS/MS) detection of free fatty acids in serum, liver, brain, and eyes. Blood glucose significantly decreased after 4 weeks of MSM treatment in T1D mice. Serum PUFA levels were significantly reduced in T2D mice compared with control mice. In contrast, treatment with SSO reversed this effect in T2D mice, exhibiting serum PUFA levels comparable to control mice. Serum triglycerides were significantly increased in both diabetic models compared to nondiabetic control, mimicking diabetes in people. High-density lipoprotein (HDL) was significantly increased in T1D receiving MSM+SSO and all T2D treatment groups. A corresponding significant decrease in non-HDL cholesterol was seen in T2D mice in all treatment groups. MSM+SSO treatment's effects on HDL and non-HDL cholesterol and PUFA metabolism could lead to improved clinical outcomes in diabetics by improving the lipid profile.